港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

劲方医药-B

32.260

-1.240-3.70%

成交量：108.40万

成交额：3,501.69万

市值：119.36亿

市盈率：-4.60

高：34.240

开：32.980

低：31.040

收：33.500

52周最高：52.900

52周最低：19.600

股本：3.70亿

香港流通股本：3.38亿

量比：0.97

换手率：0.32%

股息：- -

股息率：- -

每股收益(LYR):-7.009

净资产收益率：--

总资产收益率：-12.49%

市净率：5.70

市盈率(LYR):-4.60

市销率: 79.35

数据加载中...

总览公司新闻资讯公告

劲方医药-B午前涨近5% 西南证券首次覆盖建议积极关注

港股异动 | 劲方医药-B(02595)午前涨超6% GDF15/IL-6双抗注射液获CDE临床受理

劲方医药－Ｂ(02595)股价上升5.202%，现价港币$36.0

阿斯达克财经

西南证券：首次覆盖劲方医药(02595)建议积极关注产品进度全球领先

智通财经网

劲方医药-B更新4月股份变动月报表，股本维持不变

格隆汇个股放量排行榜 | 5月3日

格隆汇个股放量排行榜 | 5月1日

异动解读 | 劲方医药-B盘中大跌5.28%，澄清专利争议后市场情绪仍未消化

劲方医药-B(02595)：Rev Med发出函件所涉主体、产品、争议事项均与公司无关

劲方医药宣布GFH276基于自主知识产权平台开发

异动解读 | 澄清与Revmed函件无关，劲方医药-B盘中大跌11.85%

劲方医药澄清：Revmed函件所涉主体、产品或争议事项均与公司无关

劲方医药－Ｂ(02595)股价下跌9.48%，现价港币$43.54

阿斯达克财经

劲方医药-B午前涨超7% 两项GFH375/VS-7375临床前研究入选突破性研究摘要

劲方医药-B午前涨超4% 公司公布泛RAS抑制剂GFH276临床前研究数据

异动解读 | 核心产品获突破性疗法认定，劲方医药-B盘中大涨5.55%

劲方医药-B（02595）2025年收入稳增研发投入加码资产负债表显著改善

劲方医药-B拟回购最多10%股份

国金证券：首次覆盖劲方医药-B(02595)给予“买入”评级目标价为55.63港元

港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02595/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":32.26,"timestamp":1779782902006,"preClose":33.5,"halted":0,"volume":1083955,"delay":0,"changeRate":-0.03701492537313439,"floatShares":338000000,"shares":370000000,"eps":-7.0093492672988,"marketStatus":"未开盘","change":-1.24,"latestTime":"05-26 16:08:22","open":32.98,"high":34.24,"low":31.04,"amount":35016880,"amplitude":0.095522,"askPrice":32.26,"askSize":200,"bidPrice":32.14,"bidSize":4200,"shortable":3,"etf":0,"ttmEps":-6.194093817098973,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":33.5,"openAndCloseTimeList":[[1779759000000,1779768000000],[1779771600000,1779782400000]],"volumeRatio":0.967063,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-12.49%","roe":"--","lyrEps":-7.009349,"volumeRatio":0.967063,"shares":370000000,"dividePrice":0,"high":34.24,"amplitude":0.095522,"preClose":33.5,"low":31.04,"week52Low":19.6,"pbRate":"5.70","psRate":"79.35","week52High":52.9,"institutionHeld":0,"latestPrice":32.26,"committee":0.909091,"eps":-7.0093492672988,"divideRate":0,"volume":1083955,"delay":0,"ttmEps":-6.194093817098973,"open":32.98,"prevYearClose":23.78,"prevWeekClose":33.5,"prevMonthClose":43.14,"prevQuarterClose":33.42,"fiveDayClose":34.44,"twentyDayClose":49.46,"sixtyDayClose":28.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1776268800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-05-22","current":-5.206709,"percent":0.919753,"low":-19.62221,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"high":-5.69787,"avg":-10.419693,"sd":2.620978,"marketCap":12407282105},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105}],"updateTime":1779792846847},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636892567","title":"劲方医药-B午前涨近5% 西南证券首次覆盖建议积极关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892567","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636892567?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 11:23","pubTimestamp":1779247380,"startTime":"0","endTime":"0","summary":"　　劲方医药-B盘中涨超6%，截至发稿，股价上涨4.62%，现报35.80港元，成交额1795.20万港元。　　CDE官网最新公示显示，劲方医药申报的GFS202A注射液临床试验申请，已于5月12日正式获得受理，受理号为CXSL2600491。　　西南证券发布研报称，公司以产品矩阵进军胰腺癌、非小细胞肺癌、恶病质等大适应症市场，力求覆盖 1L 及各线治疗，产品进度全球领先；预计 2026-2028 年收入分别为 0.85/1.02/3.11亿元，分别同比-35%/+20%/+205%，首次覆盖，建议积极关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-20/doc-inhyphnm9433137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","600369","BK0012","BK0028","BK0276","BK1161","BK0183","BK1515","BK1574","02595","09939","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894070","title":"港股异动 | 劲方医药-B(02595)午前涨超6% GDF15/IL-6双抗注射液获CDE临床受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894070","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636894070?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 11:16","pubTimestamp":1779246963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B午前涨超6%，截至发稿，涨5.08%，报35.96港元，成交额1681.63万港元。消息面上，CDE官网最新公示显示，劲方医药申报的GFS202A注射液临床试验申请，已于5月12日正式获得受理，受理号为CXSL2600491。公开资料显示，GFS202A为全球首款靶向GDF15与IL-6的双特异性抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4588","LU1223082196.USD","LU1223082519.USD","BK1574","09939","CDE","02595","LU1223083913.SGD","BK4017","BK4585","159938","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636892507","title":"劲方医药－Ｂ(02595)股价上升5.202%，现价港币$36.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892507","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636892507?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 11:09","pubTimestamp":1779246540,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午11:09比前收市价上升5.202%，现股价为港币$36.0。至目前为止，今日最高价为$36.0，而最低价为$34.22。总成交量为30.72万股，总成交金额为港币$1.08千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605201884/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605201884/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","BK1515","159938","02595","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700397","title":"西南证券：首次覆盖劲方医药(02595)建议积极关注 产品进度全球领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700397","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635700397?lang=zh_cn&edition=fundamental","pubTime":"2026-05-15 15:54","pubTimestamp":1778831677,"startTime":"0","endTime":"0","summary":"公司专注于肿瘤、自免和炎症性疾病的新治疗方案开发，已构建起一款包括8款候选产品的药物管线，包含1款已上市药物GFH925/氟泽雷塞以及5款临床阶段药物，具备全球第一梯队的RAS疗法矩阵以及差异化的非肿瘤领域多元临床管线。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260515/20260515155514_32942.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260515/20260515155514_32942.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02595","09939","BK0028","BK1574","159938","BK0188","600369","BK0012","BK1161","BK0183","BK1515","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183692720","title":"劲方医药-B更新4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183692720","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183692720?lang=zh_cn&edition=fundamental","pubTime":"2026-05-07 16:37","pubTimestamp":1778143041,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年5月7日披露了截至2026年4月30日的证券变动月报表。报告显示，公司本月已发行股本数与上月相比无变化，股本维持稳定。公告披露，公司注册资本由两部分组成：H股338,029,020股，面值人民币0.1元，合计人民币33,802,902元；未上市普通股32,337,610股，面值人民币0.1元，合计人民币3,233,761元。两者合计股数为370,366,630股，注册股本总额人民币37,036,663元，与上月底持平。公司确认，其公众持股比例符合香港联合交易所有限公司的相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604150","title":"格隆汇个股放量排行榜 | 5月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604150","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632604150?lang=zh_cn&edition=fundamental","pubTime":"2026-05-03 17:30","pubTimestamp":1777800604,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/03173056983654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02676","02637","00133","00501","02276","00220","02516","00259","02579","00719","00800","06979","09990","00815","00981","00780","02408","00148","00178","00558","00650","00659","00709","01211","00363","01643","01765","06938","09903","09999","00880","06821","00189","09927","02443","00909","01429","06110","02489","00568","01833","02583","02595","02655","00019","01458","00168","02656","01347","02687"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632158966","title":"格隆汇个股放量排行榜 | 5月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632158966","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632158966?lang=zh_cn&edition=fundamental","pubTime":"2026-05-01 17:30","pubTimestamp":1777627804,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/01173056970876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00659","02595","09927","01429","00650","01347","01643","01765","00189","01211","00568","00178","01458","09999","02276","00220","00363","00709","00800","00815","02443","00558","00880","00148","00259","00168","00133","09903","00501","00981","02489","00780","02656","00719","01833","02637","00019","00909","02579","02655","02583","02687","02408","02516","06938","09990","06979","02676","06110","06821"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1137853103","title":"异动解读 | 劲方医药-B盘中大跌5.28%，澄清专利争议后市场情绪仍未消化","url":"https://stock-news.laohu8.com/highlight/detail?id=1137853103","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137853103?lang=zh_cn&edition=fundamental","pubTime":"2026-04-29 09:45","pubTimestamp":1777427130,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中大跌5.28%，引起了市场的广泛关注。消息面上，公司此前发布公告，澄清Revolution Medicines Inc.向第三方公司发出的有关RAS抑制剂专利及商业秘密争议的函件，所涉主体、产品及争议事项均与公司无关。公司强调，其旗下Pan RAS抑制剂GFH276具备完全独立、自主原创的知识产权，相关专利保护期预计可至2044年，不存在类似侵权风险。然而，尽管公司已发布澄清声明，市场情绪仍未完全消化，导致股价延续前一交易日的跌势。此次股价波动凸显了市场对生物科技公司知识产权状况的高度敏感，即使在公司主动澄清后，投资者信心仍需时间恢复。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630343326","title":"劲方医药-B(02595)：Rev Med发出函件所涉主体、产品、争议事项均与公司无关","url":"https://stock-news.laohu8.com/highlight/detail?id=2630343326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630343326?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 12:36","pubTimestamp":1777351016,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，公司近期注意到若干报导，涉及 Revolution Medicines Inc.(“RevMed”)向第三方公司发出有关RAS抑制剂专利及商业秘密争议的函件。公司特此澄清并强调：Rev Med发出函件所涉主体、产品、争议事项均与公司无关，劲方Pan RAS抑制剂GFH276具备完全独立、自主原创的知识产权，不存在类似侵权或商业秘密争议风险。劲方针对Pan RAS抑制剂项目已构建全面的全球专利布局，涵盖GFH276化合物结构的专利已于2025年3月6日正式公开，专利保护期预计可至2044年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","02595","BK1574","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185566851","title":"劲方医药宣布GFH276基于自主知识产权平台开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185566851","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185566851?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 12:31","pubTimestamp":1777350672,"startTime":"0","endTime":"0","summary":"劲方医药（上海）有限公司近日披露，其创新药物GFH276完全基于公司独立自主的知识产权体系研发完成。该候选药物从早期发现到临床前研究阶段，均依托企业自主研发的技术平台推进，体现了公司在原创药物开发领域的核心竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186333823","title":"异动解读 | 澄清与Revmed函件无关，劲方医药-B盘中大跌11.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186333823","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186333823?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 12:31","pubTimestamp":1777350670,"startTime":"0","endTime":"0","summary":"劲方医药-B今日盘中股价大幅下跌11.85%，引发了市场关注。消息面上，劲方医药（上海）股份有限公司发布声明，澄清Revmed往来函件中提及的所有实体、产品或争议事项均与本公司完全无关。市场分析认为，股价的剧烈波动可能与此前市场对公司可能卷入相关争议的担忧有关，公司的澄清声明旨在消除误解。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110941813","title":"劲方医药澄清：Revmed函件所涉主体、产品或争议事项均与公司无关","url":"https://stock-news.laohu8.com/highlight/detail?id=1110941813","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110941813?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 12:30","pubTimestamp":1777350611,"startTime":"0","endTime":"0","summary":"劲方医药（上海）股份有限公司发布声明称，Revmed往来函件中提及的所有实体、产品或争议事项均与本公司完全无关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332326","title":"劲方医药－Ｂ(02595)股价下跌9.48%，现价港币$43.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332326","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630332326?lang=zh_cn&edition=fundamental","pubTime":"2026-04-28 11:25","pubTimestamp":1777346700,"startTime":"0","endTime":"0","summary":"[下跌股]劲方医药－Ｂ(02595) 股价在上午11:25比前收市价下跌9.48%，现股价为港币$43.54。至目前为止，今日最高价为$49.56，而最低价为$43.54。总成交量为153.68万股，总成交金额为港币$6.977千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604281729/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604281729/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","159938","02595","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629899655","title":"劲方医药-B午前涨超7% 两项GFH375/VS-7375临床前研究入选突破性研究摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2629899655","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629899655?lang=zh_cn&edition=fundamental","pubTime":"2026-04-24 11:50","pubTimestamp":1777002600,"startTime":"0","endTime":"0","summary":"　　劲方医药-B午前股价上涨7.34%，现报48.58港元，成交额5261.004万港元。　　4月23日，据劲方医药-B官微消息，公司宣布，GFH375/VS-7375多项临床前研究成果登陆2026年美国癌症研究协会年会壁报展示，其中两项研究数据入选突破性研究摘要。目前，GFH375/VS-7375多项单药和联合疗法试验正在国内外进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-24/doc-inhvqmqh4794330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","BK4085","09939","02595","VS","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096870","title":"劲方医药-B午前涨超4% 公司公布泛RAS抑制剂GFH276临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096870","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629096870?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 11:54","pubTimestamp":1776830040,"startTime":"0","endTime":"0","summary":"　　劲方医药-B盘中涨近6%，截至发稿，股价上涨4.41%，现报45.94港元，成交额2121.73万港元。　　劲方医药宣布，公司自主开发的口服Pan RAS抑制剂GFH276临床前研究数据，于当地时间4月21日登陆美国癌症研究协会年会壁报展示。　　此外，GFH276与西妥昔单抗、化疗药物或PD-1单抗分别联用的动物实验中，可展现显著的抑瘤增效及无瘤生存期延长。据悉，GFH276为全球第三款进入临床试验的Pan RAS抑制剂，并在临床早期数据中显示契合临床前疗效及安全性的初步结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-22/doc-inhvixkk6243796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02595","BK1161","159938","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138488804","title":"异动解读 | 核心产品获突破性疗法认定，劲方医药-B盘中大涨5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138488804","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138488804?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 11:34","pubTimestamp":1776828886,"startTime":"0","endTime":"0","summary":"劲方医药-B(02595)今日盘中大幅上涨5.55%，引起了市场的高度关注。消息面上，公司核心产品GFH375获得第二项突破性疗法认定，成为国内首个KRAS G12D抑制剂单药治疗方案被纳入胰腺癌突破性疗法认定名单，此前该产品已获得非小细胞肺癌（NSCLC）的突破性疗法认定。这一进展显著提振了市场对公司RAS靶点药物研发布局的信心。此外，公司披露的年度报告显示，全年实现收入1.30亿元人民币，同比增长24.4%；研发投入达3.32亿元人民币，较上年进一步加码，资产负债表结构也得到显著改善。尽管归母净利润仍处于亏损状态，但核心管线的连续突破被视为公司长期价值的重要支撑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163605522","title":"劲方医药-B（02595）2025年收入稳增 研发投入加码 资产负债表显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1163605522","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163605522?lang=zh_cn&edition=fundamental","pubTime":"2026-04-17 22:54","pubTimestamp":1776437647,"startTime":"0","endTime":"0","summary":"根据年度报告披露，劲方医药-B在截至2025年12月31日止年度实现收入1.30亿元人民币，较2024年的1.05亿元增长24.4%。同期销售成本为46.61百万元人民币，其他收入及收益为34.81百万元人民币，研发成本则达到3.32亿元人民币，较上年的2.82亿元有所上升。综上所述，劲方医药-B在2025年度的收入与研发投入均有不同程度提升，核心产品管线稳步推进，资产负债表结构也显著改善。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199390862","title":"劲方医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1199390862","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199390862?lang=zh_cn&edition=fundamental","pubTime":"2026-04-17 22:51","pubTimestamp":1776437495,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司最新公告显示，该公司已获董事会批准一项股份购回授权，将最多回购不超过已发行股本的10%。截至本次公告基准日，公司已发行股份约3.70亿股，按此估算，此次购回规模最高可达约3703.67万股。若该授权在2026年5月11日的股东大会上获批，公司将在授权期间根据市场情况适时执行购回，并于适用法律及规则所允许的范围内对购回股份进行处理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406715","title":"国金证券：首次覆盖劲方医药-B(02595)给予“买入”评级 目标价为55.63港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627406715?lang=zh_cn&edition=fundamental","pubTime":"2026-04-15 14:48","pubTimestamp":1776235705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，预计劲方医药-B26/27/28年销售收入为1.46/1.60/3.35亿元，同比+12.3%/+9.4%/+109.1%，归母净利润为-1.85/-1.84/-2.36亿元。基于DCF模型估值，计算合理市值为179.7亿元，对应合理目标价为55.63港元/股。首次覆盖，给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","09939","02595","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627479216","title":"港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2627479216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627479216?lang=zh_cn&edition=fundamental","pubTime":"2026-04-15 10:21","pubTimestamp":1776219660,"startTime":"0","endTime":"0","summary":"4月15日，创新药概念股上涨，$劲方医药-B$涨超9%，$信达生物$涨超4%，$恒瑞医药$、$石药集团$跟涨。重点创新药企/生物制药公司将成为受益者，如$恒瑞医药$、石药集团、信达生物以及其他跨国公司。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"91f24949debf4aed7e22faec526c7ddd","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428631.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗指恒瑞等创新药企有望受益","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU0980610538.SGD","SG9999004220.SGD","BK1521","LU2097828714.EUR","LU1807302812.USD","LU2417539215.USD","LU0648001328.SGD","BK1574","LU2097828631.EUR","LU0314106906.USD","LU2456880835.USD","BK4534","LU2462157665.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU2039709279.SGD","LU0314109678.HKD","LU1969619763.USD","LU0359201612.USD","BK4566","IE00BSNM7G36.USD","LU2328871848.SGD","IE0008369823.USD","LU0098860793.USD","LU1152091754.HKD","LU1226287792.SGD","LU0128525689.USD","IE0008368742.USD","BK4588","LU0315179316.USD","LU1008478684.HKD","LU1813983027.USD","LU2097828805.USD","LU0359201885.HKD","IE00BZ08YR35.GBP","02595","IE00B543WZ88.USD","LU1226288253.USD","LU0880133367.SGD","LU2125154778.USD","LU2097828557.USD","LU1244550494.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":105,"code":"91000000","status":"200"}]}}